“…The main characteristics and results of the human studies evaluating the potential reno-protective effects of PDE5Is are summarized in Table 1 [17,24,38,39]. The main characteristics and results of the animal studies on currently proposed AKI models evaluating the potential reno-protective effects of sildenafil, tadalafil, icariin, vardenafil, zaprinast-udenafil are summarized in Table 2 [23,30,, Table 3 [29,35,45,49,[62][63][64][65][66][67][68][69][70][71][72][73][74], Table 4 [18,75,76], Table 5 [45,77,78], and Table 6 [21,40,79,80], respectively. The main characteristics and results of the animal studies in the AKI-CKD transition spectrum (focusing on renal function and/or structure alterations for up to three months, not fulfilling the KDIGO definition for CKD [6]) evaluating the potential reno-protective effects of sildenafil, tadalafil, icariin, vardenafil, zaprinast-udenafil are summarized in Table A1 [109,110], respectively (Appendix B).…”